Published on:

Matrixx Initiatives receives warning letter from FDA

The FDA issued a warning letter to Matrixx Initiatives, Inc., asserting that the company is in violation of its product safety regulations. According to the FDA, Matrixx failed to file a new drug application for its Zicam Cold Remedy Nasal Gel and Zicam Cold Remedy Gel Swabs. More concerning, those products are misbranded for failing to adequately warn of product risks.

To read more about the FDA Zicam product safety warning.